Bronnen:
- De Philippis C, Legrande F, Bramanti S, et al. Checkpoint inhibitor treatment before haploidentical transplantation in relapsed or refractory Hodgkin lymphoma (HL) patients is associated with higher PFS without increased toxicities. EBMT2019, abstract LWP-6.,Clave E, Araujo IL, Alanio C, et al. Human thymopoiesis is influenced by a common genetic variant within the TCRA-TCRD locus. Science Transl Med. 2018, Sept 5.,Lorentino F, Labopin M, Ciceri F, et al. Comparable outcome after 10/10 and 9/10 HLA-matched unrelated donor stem cell transplantation (HSCT) using post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis, on behalf of the ALWP-EBMT. EBMT2019, abstract OS9-1. ,Bader P, Soerensen J, Rettinger E, et al. Real life experience in the treatment of pediatric, adolescent and young adult ALL patients using comercially available CAR-T-cells. EBMT2019, abstract OS9-6. ,EBMT receives a regulatory qualification from the European Medicine Agency (EMA) on the use of its patient registry to support novel CAR T-cell therapies. www.ebmt.org, 1-3-2019.